Abstract

PurposeTo evaluate the efficacy of proton beam therapy (PBT) for pediatric patients with advanced neuroblastoma.MethodsPBT was conducted at 21 sites in 14 patients with neuroblastoma from 1984 to 2010. Most patients were difficult to treat with photon radiotherapy. Two and 6 patients were classified into stages 3 and 4, respectively, and 6 patients had recurrent disease. Seven of the 8 patients who received PBT as the initial treatment were classified as the high risk group. Twelve patients had gross residual disease before PBT and 2 had undergone intraoperative radiotherapy before PBT. Five patients received PBT for multiple sites, including remote metastases. Photon radiotherapy was used in combination with PBT for 3 patients. The PBT doses ranged from 19.8 to 45.5 GyE (median: 30.6 GyE).ResultsSeven patients are alive with no evidence of disease, 1 is alive with disease progression, and 6 died due to the tumor. Recurrence in the treatment field was not observed and the 3-year locoregional control rate was 82%. Severe acute radiotoxicity was not observed, but 1 patient had narrowing of the aorta and asymptomatic vertebral compression fracture at 28 years after PBT, and hair loss was prolonged in one patient.ConclusionPBT may be a better alternative to photon radiotherapy for children with advanced neuroblastoma, and may be conducted safely for patients with neuroblastoma that is difficult to manage using photon beams.

Highlights

  • Neuroblastoma is the most common extracranial solid tumor in children

  • Aggressive treatment is conducted in these cases because they are highly sensitive to radiotherapy and chemotherapy

  • proton beam therapy (PBT) was conducted because photon beam radiotherapy was difficult due to a large irradiation area involving normal organs such as the liver, heart, and gastrointestinal tract for 8 patients

Read more

Summary

Introduction

Neuroblastoma is the most common extracranial solid tumor in children. Half of newly diagnosed patients present with high risk disease that is widely metastatic and has large and invasive lesions in the advanced stage. Aggressive treatment is conducted in these cases because they are highly sensitive to radiotherapy and chemotherapy. Despite recent progress with systemic therapy, the treatment outcome in high risk neuroblastoma is poor [1,2,3,4,5]. Advanced neuroblastoma often recurs and the prognosis after recurrence is extremely poor [6,7,8], with Garaventa et al finding survival rates of only 6.6% and 1.5% in patients with progression and relapse disease [7]. The superiority of the dose distribution in proton

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call